Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Completed Not applicable Interventional Results available

The EvAluation of TaBlo In-CLinic and In-HOme

NCT02460263
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 16, 2026, 1:04 AM EDT
Terminated Not applicable Interventional

A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement

NCT01644526
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Hemoaccess Valve System
Device
Lead sponsor
Diaxamed LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 16, 2026, 1:04 AM EDT
Withdrawn Not applicable Interventional

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B

NCT03519360
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UFR-restricted dialysis, UFR-unrestricted dialysis
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System

NCT04655989
View directory record Official record
Conditions
Dialysis, Chronic Renal Failure
Interventions
DBB-EXA ES Hemodialysis System
Device
Lead sponsor
Nikkiso America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Detroit, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 16, 2026, 1:04 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598273
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
68
States / cities
Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Prefistula Forearm Exercise in Pts Requiring Chronic HD Therapy

NCT03988270
View directory record Official record
Conditions
Arterio-venous Fistula, Kidney Failure, Hemodialysis Access Failure
Interventions
Exercise
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03636269
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

NCT02741323
View directory record Official record
Conditions
HIV Infections, Kidney Diseases
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

The Measurement of Insulin Resistance in Peritoneal Dialysis Patients

NCT01119196
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Icodextrin dialysate
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Prebiotics in Peritoneal Dialysis

NCT03265639
View directory record Official record
Conditions
End Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions
P-inulin
Dietary Supplement
Lead sponsor
Ali Ramezani
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 16, 2026, 1:04 AM EDT
Completed No phase listed Observational

Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure

NCT00760162
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Not listed
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 16, 2026, 1:04 AM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access

NCT06712251
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Interventions
Velocity pAVF System
Device
Lead sponsor
Venova Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Riverside, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 16, 2026, 1:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

NCT05287945
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Orellanine
Drug
Lead sponsor
Oncorena AB
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01286012
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Tempe, Arizona • Granada Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial

NCT03241511
View directory record Official record
Conditions
Chronic Periodontitis, End Stage Renal Disease
Interventions
Test
Other
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 16, 2026, 1:04 AM EDT
Terminated Phase 1 Interventional

Testosterone Replacement in Renal Failure

NCT02712944
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone, Saline
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Results available

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

NCT05335005
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Failure, Chronic
Interventions
MK-2060
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 16, 2026, 1:04 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 16, 2026, 1:04 AM EDT